Murchinson’s Aprea Therapeutics APRE Stock Holding History

Murchinson’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-340,139	Closed	-$290K	–	101
2025 Q4	$290K	Buy	+340,139	New	+$418K	0.05%	57

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Murchinson's APRE Position: Q1 2026 in Review

Murchinson sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 340,139 shares — an estimated $290K sold.

Murchinson first reported a position in APRE in Q4 2025 and held it in 1 quarter. The position peaked at $290K in Q4 2025. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Murchinson reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
Murchinson sold 340,139 Aprea Therapeutics shares in Q1 2026, an estimated $290K.
Murchinson first reported a position in Aprea Therapeutics in Q4 2025 and held it in 1 quarter.
Murchinson's Aprea Therapeutics position peaked at $290K in Q4 2025.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Murchinson's 13F filing for Q1 2026, filed 15 May 2026.